UNIGE document Scientific Article
previous document  unige:37151  next document
add to browser collection
Title

A phase I dose-escalation study of MSC1992371A, an oral inhibitor of aurora and other kinases, in advanced hematologic malignancies

Authors
Graux, Carlos
Sonet, Anne
Maertens, Johan
Duyster, Justus
Greiner, Jochen
Martinelli, Giovanni
Hess, Dagmar
show hidden authors show all authors [1 - 16]
Published in Leukemia Research. 2013, vol. 37, no. 9, p. 1100-6
Abstract A phase I dose-escalation study of MSC1992371A, an oral aurora kinase inhibitor, was carried out in patients with hematologic malignancies. Patients received escalating doses either on days 1-3 and 8-10 (n=36) or on days 1-6 (n=39) of a 21-day cycle. The maximum tolerated doses were 37 and 28 mg/m(2)/day, respectively. Dose-limiting toxicities included severe neutropenia with infection and sepsis, mucositis/stomatitis, and diarrhea. Complete responses occurred in 3 patients. Four disease-specific expansion cohorts then received the dose and schedule dictated by the escalation phase but the study was prematurely discontinued due to hematologic and gastrointestinal toxicity at clinically effective doses.
Keywords Administration, OralAdultAgedAged, 80 and overDose-Response Relationship, DrugFemaleFollow-Up StudiesHematologic Neoplasms/drug therapy/enzymologyHumansMaleMaximum Tolerated DoseMiddle AgedPrognosisProtein Kinase Inhibitors/pharmacokinetics/therapeutic useRemission InductionTissue Distribution
Identifiers
PMID: 23746966
Full text
Article (Published version) (526 Kb) - public document Free access
Structures
Citation
(ISO format)
GRAUX, Carlos et al. A phase I dose-escalation study of MSC1992371A, an oral inhibitor of aurora and other kinases, in advanced hematologic malignancies. In: Leukemia Research, 2013, vol. 37, n° 9, p. 1100-6. https://archive-ouverte.unige.ch/unige:37151

279 hits

125 downloads

Update

Deposited on : 2014-06-04

Export document
Format :
Citation style :